Skip to content

Public FDA record

Z-0371-2016: Valeant Pharmaceuticals North America Model No. Spag-2 Small Particle Size Aerosol Generator SPAG-2 6000

Recall record Z-0371-2016 for Valeant Pharmaceuticals North America LLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0371-2016
Company in FDA record
Valeant Pharmaceuticals North America LLC
FDA classification date
Dec 4, 2015
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

SPAG-2 6000 Lot J3522070 was released to commerce without being tested for particle size per quality control procedure SPAG-2515.

Source facts

Action
Valeant Pharmaceuticals International issued recall letter/return response form dated 9/11/2015 via 2nd day air service Customers were requested to check their inventory for the SPAG-2 device and sgregate it for return shipment.
Initiated
2015-09-14
Root cause
Under Investigation by firm
Terminated
2017-06-27
Distribution
AL, AZ, CA, CO, IL, OH, MO, NC, NY, PA., SC, UT and TX
Recall number
Z-0371-2016
Recall status
Terminated
CDRH record ID
140162
FDA classified
2015-12-04
Recall event number
72198

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗